{"name":"Shalvata Mental Health Center","slug":"shalvata-mental-health-center","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Ketamine (1st phase)","genericName":"Ketamine (1st phase)","slug":"ketamine-1st-phase","indication":"Treatment-resistant depression","status":"marketed"},{"name":"Ketamine (2st phase)","genericName":"Ketamine (2st phase)","slug":"ketamine-2st-phase","indication":"Treatment-resistant depression (marketed/clinical use)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Hair Sample","genericName":"Hair Sample","slug":"hair-sample","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Hair Sample","genericName":"Hair Sample","slug":"hair-sample","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Ketamine (1st phase)","genericName":"Ketamine (1st phase)","slug":"ketamine-1st-phase","phase":"marketed","mechanism":"Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks glutamate signaling in the brain.","indications":["Treatment-resistant depression","Acute suicidal ideation and behavior","Chronic pain conditions"],"catalyst":""},{"name":"Ketamine (2st phase)","genericName":"Ketamine (2st phase)","slug":"ketamine-2st-phase","phase":"marketed","mechanism":"Ketamine is a non-competitive NMDA receptor antagonist that blocks glutamate signaling in the brain, producing rapid-onset dissociative anesthesia and analgesic effects.","indications":["Treatment-resistant depression (marketed/clinical use)","Acute suicidal ideation and behavior","Anesthesia induction and maintenance","Chronic pain conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQQ1dfb0h0b05TdXBpZmNlNDltRXNHQ0RnSU1lT2F3Z21qbk52QWJmMHV0aE4zY1pmSGpMamdnWkx1eHhyX3NNNGpZYUFjam4zdDZOWGJnZ21kdk9xc2hCS1VxZUs1MjlpUkJSdUlGT1VyMFB4VHYwa2N1b2o1UjJGc2F2QkpPUmJPUnJjSWFRdWtSUmJ6ZmtxdExvNl9rSF83czZ5VVBEWDI2VU9ORE05SjJmdlBDdlE1UzJnWm8xNC1aOFNpUTFNTDVLMjVaVnhFVk9WUzQ3TGZNWS1IZ1E?oc=5","date":"2026-03-29","type":"pipeline","source":"News-Graphic.com","summary":"In Israel, air raid sirens spark anxiety and dilemmas - News-Graphic.com","headline":"In Israel, air raid sirens spark anxiety and dilemmas - News","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":1,"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}